Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
Status:
Recruiting
Trial end date:
2024-08-19
Target enrollment:
Participant gender:
Summary
To demonstrate the efficacy of VERU-111 (Sabizabulin) in the treatment of metastatic
castration-resistant prostate cancer in patients who have failed prior treatment with at
least one androgen receptor targeting agent as measured by radiographic progression-free
survival.